Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin

Advances in Therapy

Volumn 29, Issue 5, 2012, Pages 442-455

  Haas, Wolfgang ^a   Gearinger, Lynne S ^a   Hesje, Christine K ^a   Sanfilippo, Christine M ^a   Morris, Timothy W ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

Antimicrobial efficacy; Bacterial conjunctivitis; Besifloxacin; Fluoroquinolone; Ophthalmic suspension

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BESIFLOXACIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; METICILLIN; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONJUNCTIVITIS; CONTROLLED STUDY; DOLOSIGRANULUM PIGRUM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PARALLEL DESIGN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ADMINISTRATION, OPHTHALMIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZEPINES; BACTERIA; BACTERIOLOGICAL TECHNIQUES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, BACTERIAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84863716560     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0023-y     Document Type: Article

References (34)

1. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med. 2008;75:507-12.
2. O'Brien TP, Jeng BH, McDonald M, Raizman MB. Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin. 2009;25:1953-61.
3. Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86:5-17. (Pubitemid 351512464)
4. Golde KT, Gardiner MF. Bacterial conjunctivitis in children: a current review of pathogens and treatment. Int Ophthalmol Clin. 2011;51:85-92.
5. American Academy of Ophthalmology. American Academy of Ophthalmology Cornea/External Disease Panel; Preferred Practice Pattern Guidelines. Conjunctivitis. San Francisco, CA: American Academy of Ophthalmology; 2008.
6. Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369-79.
7. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008;145:951-8.
8. Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011;152:567-74.
9. Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 2008;115:51-6. (Pubitemid 350309422)
10. Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol. 2010;4:215-25.
11. Carter NJ, Scott LJ. Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70:83-97.
12. Bertino JS, Zhang JZ. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Exp Opin Pharmacother. 2009;10:2545-54.
13. Haas W, Pillar CP, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552-60.
14. Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65:1441-7.
15. Sanfilippo CM, Hesje CK, Haas W, Morris TW. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin. Chemotherapy. 2011;57:363-71.
16. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116:1615-23.
17. Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31:514-26.
18. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159-69.
19. DeLeon J, Silverstein BE, Allaire C, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012;32:303-17.
20. Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clin Ther. 2011;33:13-26.
21. Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981;1:523-34. (Pubitemid 12105721)
22. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112:29S-33S.
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement M100-S21. 31. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2011.
24. Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011;249:111-9.
25. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. Washington, D.C.: ASM Press; 2007.
26. Leighton C, Piper D, Gunerman-King J. Pneumococcal conjunctivitis at an elementary school-Maine, September 20-December 6, 2002. MWR Morb Mortal Wkly Rep. 2003;52:64-6.
27. Barker JH, Musher DM, Silberman R, Phan HM, Watson DA. Genetic relatedness among nontypeable pneumococci implicated in sporadic cases of conjunctivitis. J Clin Microbiol. 1999;37:4039-41.
28. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112-21. (Pubitemid 36337322)
29. Sanfilippo CM, Haas W, Hesje CK, Morris TW. Strain ST448 causes the majority of pneumococcal conjunctivitis cases. Abstract A226. Paper presented at: Annual meeting of The Association for Research in Vision and Ophthalmology; May 6, 2012; Ft. Lauderdale, Florida, USA.
30. Aguirre M, Morrison D, Cookson BD, Gay FW, Collins MD. Phenotypic and phylogenetic characterization of some Gemella-like organisms from human infections: description of Dolosigranulum pigrum gen. nov., sp. nov. J Appl Bacteriol. 1993;75:608-12. (Pubitemid 24025177)
31. Laclaire L, Facklam R. Antimicrobial susceptibility and clinical sources of Dolosigranulum pigrum cultures. Antimicrob Agents Chemother. 2000;44:2001-3. (Pubitemid 30422966)
32. Tauber S, Cupp G, Garber R, Bartell J, Vohra F, Stroman D. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Adv Ther. 2011;28:566-74.
33. Dong Q, Brulc JM, Iovieno A, et al. Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis Sci. 2011;52:5408-13.
34. Bertino JS. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol. 2009;3:507-21.